Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action.
Eisenberger MA, Laufer M, Vogelzang NJ, Sartor O, Thornton D, Neubauer BL, Sinibaldi V, Lieskovsky G, Carducci MA, Zahurak M, Raghavan D. Eisenberger MA, et al. Among authors: sinibaldi v. Urology. 2004 Jan;63(1):114-9. doi: 10.1016/j.urology.2003.08.017. Urology. 2004. PMID: 14751361 Clinical Trial.
Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.
Keizman D, Zahurak M, Sinibaldi V, Carducci M, Denmeade S, Drake C, Pili R, Antonarakis ES, Hudock S, Eisenberger M. Keizman D, et al. Among authors: sinibaldi v. Clin Cancer Res. 2010 Nov 1;16(21):5269-76. doi: 10.1158/1078-0432.CCR-10-1928. Epub 2010 Oct 26. Clin Cancer Res. 2010. PMID: 20978144 Free PMC article. Clinical Trial.
The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation.
Keizman D, Huang P, Antonarakis ES, Sinibaldi V, Carducci MA, Denmeade S, Kim JJ, Walczak J, Eisenberger MA. Keizman D, et al. Among authors: sinibaldi v. Prostate. 2011 Nov;71(15):1608-15. doi: 10.1002/pros.21377. Epub 2011 Mar 22. Prostate. 2011. PMID: 21432863 Free PMC article.
Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.
Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger MA, Sinibaldi V, Boursi B, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Berger R, Carducci MA. Keizman D, et al. Among authors: sinibaldi v. Eur J Cancer. 2012 May;48(7):1031-7. doi: 10.1016/j.ejca.2012.02.050. Epub 2012 Mar 10. Eur J Cancer. 2012. PMID: 22409947
Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram.
Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Rosenbaum E, Kovel S, Pili R, Sinibaldi V, Carducci MA, Hammers H, Eisenberger MA, Sella A. Keizman D, et al. Among authors: sinibaldi v. Oncologist. 2012;17(12):1508-14. doi: 10.1634/theoncologist.2012-0125. Epub 2012 Sep 12. Oncologist. 2012. PMID: 22971522 Free PMC article.
61 results